DNA X Inc (SONM)

DNA X Inc is a common stock listing on NASDAQ for a company that develops enterprise 5G communications equipment and related software. Through its operating business, the company provides rugged mobile phones for field and task workers, including the Sonim XP10, XP5plus, XP3plus, XP Pro, XP100 4G, XP400 5G, and XP3plus 5G rugged flip phones. Its connected solutions also include fixed wireless access and mobile hotspot devices such as the Sonim H100, H700, and H500-series products, along with SonimWare software and industrial-grade accessories. DNA X sells through wireless carriers, distributors, communications system integrators, and electronics resellers, serving industries such as transportation and logistics, construction, manufacturing, facilities management, energy and utilities, mining, federal government, and public safety. The company was previously known as Sonim Technologies, Inc., adopted the DNA X name in January 2026, and is headquartered in San Diego, California.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-SONM
$3.24
-26.2% Downside
Overvalued
Not available
Not available
Weak
0.0%
November 13, 2026
6.533 M
8.033 M
27.6%
82.7%
-139.9
140.8%
Valuation • Fair Value

DNA X Inc (NASDAQ-SONM) Fair Value by Valuation Model

Review the available estimates for DNA X Inc (NASDAQ-SONM), including Comps Fair Value.

Primary Valuation Read

Fair Value

$3.24

Estimated downside of 26.2% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$3.24

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for DNA X Inc (NASDAQ-SONM) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for DNA X Inc (NASDAQ-SONM)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

143.2 M

Forward revenue estimate.

EBITDA

-3.479 M

Current operating profitability reference.

EBITDA Forecast

9.22 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review DNA X Inc (NASDAQ-SONM) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for DNA X Inc (NASDAQ-SONM)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

-139.9

Lower score that deserves closer risk review.

FCF / Net Income

140.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for DNA X Inc (NASDAQ-SONM). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for DNA X Inc (NASDAQ-SONM)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

52

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for DNA X Inc (NASDAQ-SONM), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for DNA X Inc (NASDAQ-SONM) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for DNA X Inc (NASDAQ-SONM) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for DNA X Inc (NASDAQ-SONM) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for DNA X Inc (NASDAQ-SONM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for DNA X Inc (NASDAQ-SONM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ Fast Investor Answers

DNA X Inc (NASDAQ-SONM) Stock FAQ

Data-supported answers about DNA X Inc (NASDAQ-SONM), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$3.24
Estimated downside 26.2%
Valuation Rating
Overvalued
Estimated downside of 26.2%
Financial Health
Weak
Current financial-health read

The current fair value estimate for DNA X Inc (NASDAQ-SONM) is $3.24. This implies an estimated downside of 26.2% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 26.2% versus the current market price.

The current financial health read for DNA X Inc (NASDAQ-SONM) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for DNA X Inc (NASDAQ-SONM) is November 13, 2026.

The latest available data indicates no current dividend yield for DNA X Inc (NASDAQ-SONM).

The current market capitalization listed for DNA X Inc is 6.533 M.

The current enterprise value listed for DNA X Inc is 8.033 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for DNA X Inc is NASDAQ-SONM, and the stock is listed on NASDAQ.

DNA X Inc (NASDAQ-SONM) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for DNA X Inc is 27.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for DNA X Inc is 82.7%. Free float helps investors understand how much of the share base is available for public trading.